We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-11.19%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.41B
AUM Growth
-$441M
Cap. Flow
+$123M
Cap. Flow %
5.09%
Top 10 Hldgs %
73.82%
Holding
49
New
5
Increased
3
Reduced
1
Closed
6

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$130M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$28.1M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$14.8M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$12.7M
5
KA
Kineta, Inc. Common Stock
KA
+$5.48M

Top Sells

Rank Stock Value
1
CRCM
CARE.COM, INC.
CRCM
+$51.8M
2
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$14.8M
3
SENS icon
Senseonics Holdings Inc
SENS
+$7.05M
4
PXLW icon
Pixelworks
PXLW
+$1.69M
5
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$652K

Sector Composition

Rank Sector Weight
1 Healthcare 89.08%
2 Technology 1.77%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$851M 35.27%
10,275,113
– –
CBIO
2
Crescent Biopharma
CBIO
$570M
$144M 5.97%
85,841
– –
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.34B
$143M 5.91%
+4,912,306
New +$130M
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$134M 5.54%
325,771
– –
DERM
5
DELISTED
Dermira, Inc.
DERM
$97.5M 4.04%
3,506,649
– –
ARDX icon
6
Ardelyx
ARDX
$1.24B
$93M 3.85%
14,083,582
– –
SENS icon
7
Senseonics Holdings Inc
SENS
$259M
$82.2M 3.4%
1,544,413
-126,851
-8% -$7.05M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$81.1M 3.36%
6,460,851
– –
ADAP
9
DELISTED
Adaptimmune Therapeutics
ADAP
$80.3M 3.33%
12,025,999
– –
CRSP icon
10
CRISPR Therapeutics
CRSP
$4.63B
$75.6M 3.13%
3,220,728
– –
AKAO
11
DELISTED
Achaogen Inc
AKAO
$56M 2.32%
5,215,128
– –
AVEO
12
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$45.7M 1.89%
1,636,269
– –
IMMU
13
DELISTED
Immunomedics Inc
IMMU
$44.8M 1.86%
2,772,643
– –
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$44.8M 1.85%
4,586,563
+1,250,000
+37% +$12.7M
CMTA
15
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$40.6M 1.68%
2,141,697
– –
SYBX
16
DELISTED
Synlogic
SYBX
$37M 1.53%
254,627
– –
CASC
17
DELISTED
Cascadian Therapeutics, Inc.
CASC
$33.5M 1.39%
9,064,575
– –
KA
18
DELISTED
Kineta, Inc. Common Stock
KA
$32.4M 1.34%
39,691
+14,285
+56% +$5.48M
SBBP
19
DELISTED
Strongbridge Biopharma plc.
SBBP
$30M 1.24%
4,141,308
– –
RARX
20
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$29.7M 1.23%
3,493,636
– –
TNTR
21
DELISTED
Tintri, Inc. Common Stock
TNTR
$26.8M 1.11%
5,253,358
– –
XFOR icon
22
X4 Pharmaceuticals
XFOR
$372M
$25.5M 1.06%
+11,111
New +$28.1M
LXRX icon
23
Lexicon Pharmaceuticals
LXRX
$1.03B
$23.5M 0.98%
2,382,286
– –
AUPH icon
24
Aurinia Pharmaceuticals
AUPH
$1.92B
$21.8M 0.9%
4,808,483
– –
VRNA
25
DELISTED
Verona Pharma
VRNA
$14.5M 0.6%
1,219,674
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2017 Portfolio in Review

As of Q4 2017, NEA Management Company held 49 positions worth $2.41B, down 15% from $2.86B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

NEA Management Company deployed $123M of net new capital in Q4 2017, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 4,912,306 shares worth $143M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Senseonics Holdings Inc, an estimated $7.05M trimmed.

  • NEA Management Company's largest Q4 2017 buy was Rhythm Pharmaceuticals: 4,912,306 shares worth $143M.
  • NEA Management Company added most to ObsEva SA Ordinary Shares in Q4 2017, an estimated $12.7M increase.
  • NEA Management Company's biggest Q4 2017 reduction was Senseonics Holdings Inc, cutting an estimated $7.05M.
  • NEA Management Company fully exited CARE.COM, INC. in Q4 2017, selling an estimated $51.8M.
  • NEA Management Company's ten largest holdings make up 74% of its $2.41B portfolio in Q4 2017.
  • NEA Management Company opened 5 new positions and closed 6 in Q4 2017.
  • NEA Management Company's portfolio value fell 15% quarter-over-quarter to $2.41B.

Based on NEA Management Company's 13F filing for Q4 2017, filed 8 Feb 2018.